GlassScriptPhysician profile
Crit Taylor Richardson
NPI 1952744153
$6,098.03
in general payments reported to CMS, 2019-2025
27 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $198 · 2021: $667 · 2022: $1,002 · 2023: $1,631 · 2024: $1,269 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,008.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,544.91 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $567.17 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $459.01 | 2021-2024 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $453.84 | 2021-2025 | Stelara, Tremfya |
| Genzyme Corporation | $314.01 | 2022-2025 | |
| Qol Medical, LLC | $276.65 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $226.02 | 2023-2025 | Ibsrela |
| Celgene Corporation | $221.10 | 2021-2023 | Zeposia |
| Medtronic, INC. | $166.80 | 2024 | Endoflip, Pillcam |
| Pfizer INC. | $109.83 | 2020-2025 | |
| Nestle Healthcare Nutrition INC. | $90.34 | 2022-2023 | |
| Novo Nordisk INC | $90.26 | 2025 | Wegovy |
| Covidien LP | $90.08 | 2020 | |
| Enterra Medical, INC. | $73.11 | 2023 | |
| Intercept Pharmaceuticals, INC. | $58.32 | 2023 | Ocaliva |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $49.55 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $46.47 | 2020-2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $40.73 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $37.07 | 2019-2023 | Dificid |
| Braintree Laboratories, INC. | $35.62 | 2019-2023 | Suflave |
| Ultragenyx Pharmaceutical INC. | $27.23 | 2022 | |
| Intra-Sana Laboratories | $26.27 | 2022 | |
| Daiichi Sankyo INC. | $22.78 | 2025 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $22.55 | 2025 | Iqirvo |
| Apollo Endosurgery US INC | $20.31 | 2022 | |
| Allergan, INC. | $15.53 | 2020 | |
| Alnylam Pharmaceuticals INC. | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crit Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.